Evaluation
What has been checked, and how. Calculator correctness is verified on every build. On this page, model accuracy is reported only from completed runs, with every raw output published.
Calculator checks
Each calculator is run on worked examples whose expected results were derived by hand from the published formula or dosing table. This table is generated by running the calculators when the page is built, with the same code as the workspace.
| Calculator | Worked example | Expected | Computed | Result |
|---|---|---|---|---|
Wells' Criteria for Pulmonary Embolism Cardiology & Vascular | Recent surgery, HR 110, haemoptysis, PE most likely | 7 | Score 7 PE likely (score > 4) | Match |
Wells' Criteria for Pulmonary Embolism Cardiology & Vascular | Tachycardia only | 1.5 | Score 1.5 PE unlikely (score ≤ 4) | Match |
Wells' Criteria for DVT Cardiology & Vascular | Active cancer, calf swelling, pitting oedema | 3 | Score 3 DVT likely (score ≥ 2) | Match |
Wells' Criteria for DVT Cardiology & Vascular | Same findings but cellulitis equally likely | 1 | Score 1 DVT unlikely (score < 2) | Match |
CHA₂DS₂-VASc Score Cardiology & Vascular | 66-year-old man, hypertension, diabetes | 3 | Score 3 Two or more non-sex risk factors — anticoagulation recommended | Match |
CHA₂DS₂-VASc Score Cardiology & Vascular | 50-year-old woman, no other factors | 1 | Score 1 Low risk — anticoagulation not recommended | Match |
CHA₂DS₂-VASc Score Cardiology & Vascular | 70-year-old woman, no other factors | 2 | Score 2 One non-sex risk factor — anticoagulation should be considered | Match |
CHA₂DS₂-VASc Score Cardiology & Vascular | 80-year-old man, prior stroke | 4 | Score 4 Two or more non-sex risk factors — anticoagulation recommended | Match |
HEART Score Cardiology & Vascular | Highly suspicious history, non-specific ECG, age 66, 1–2 risk factors, normal troponin | 6 | Score 6 / 10 Moderate risk (4–6) | Match |
HEART Score Cardiology & Vascular | Low-risk 30-year-old | 0 | Score 0 / 10 Low risk (0–3) | Match |
TIMI Risk Score (UA/NSTEMI) Cardiology & Vascular | Six of seven criteria present | 6 | Score 6 / 7 High risk (5–7) | Match |
TIMI Risk Score (UA/NSTEMI) Cardiology & Vascular | No criteria | 0 | Score 0 / 7 Low risk (0–2) | Match |
HAS-BLED Bleeding Risk Cardiology & Vascular | Age 70, on aspirin, prior bleed | 3 | Score 3 / 9 High bleeding risk (≥ 3) | Match |
HAS-BLED Bleeding Risk Cardiology & Vascular | Age 70 only | 1 | Score 1 / 9 Low to moderate bleeding risk (0–2) | Match |
Corrected QT Interval (QTc) Cardiology & Vascular | QT 400 ms at 75 beats/min | 447 | QTc 447 ms Within normal limits | Match |
Corrected QT Interval (QTc) Cardiology & Vascular | QT 400 ms at 120 beats/min (Fridericia) | 504 | QTc 504 ms Markedly prolonged (> 500 ms) | Match |
Cockcroft-Gault Creatinine Clearance Nephrology & Electrolytes | 72-year-old man, 70 kg, creatinine 2.4 mg/dL | 27.5 | 27.5 mL/min 15–29 — severely reduced | Match |
Cockcroft-Gault Creatinine Clearance Nephrology & Electrolytes | Same patient, female | 23.4 | 23.4 mL/min 15–29 — severely reduced | Match |
Cockcroft-Gault Creatinine Clearance Nephrology & Electrolytes | Creatinine entered as 212 µmol/L | 27.5 | 27.5 mL/min 15–29 — severely reduced | Match |
eGFR — CKD-EPI 2021 (creatinine) Nephrology & Electrolytes | 60-year-old man, creatinine 1.0 mg/dL | 86 | 86 mL/min/1.73 m² GFR category G2 | Match |
eGFR — CKD-EPI 2021 (creatinine) Nephrology & Electrolytes | 60-year-old woman, creatinine 0.7 mg/dL | 99 | 99 mL/min/1.73 m² GFR category G1 | Match |
eGFR — CKD-EPI 2021 (creatinine) Nephrology & Electrolytes | 75-year-old man, creatinine 2.0 mg/dL | 34 | 34 mL/min/1.73 m² GFR category G3b | Match |
Anion Gap, Albumin Correction and Delta Ratio Nephrology & Electrolytes | Na 140, Cl 100, HCO₃ 12 | 28 | 28 mmol/L High anion gap | Match |
Anion Gap, Albumin Correction and Delta Ratio Nephrology & Electrolytes | Same with albumin 2.0 g/dL | 33 | 33 mmol/L High anion gap | Match |
Anion Gap, Albumin Correction and Delta Ratio Nephrology & Electrolytes | Na 140, Cl 104, HCO₃ 24 | 12 | 12 mmol/L Normal anion gap | Match |
Fractional Excretion of Sodium (FENa) Nephrology & Electrolytes | Urine Na 14, serum Na 140, urine Cr 90, serum Cr 2.8 | 0.31 | 0.31% < 1% — suggests prerenal cause | Match |
Fractional Excretion of Sodium (FENa) Nephrology & Electrolytes | Urine Na 60, serum Na 138, urine Cr 40, serum Cr 3.0 | 3.26 | 3.26% > 2% — suggests intrinsic tubular injury | Match |
Sodium Corrected for Hyperglycaemia Nephrology & Electrolytes | Na 128, glucose 600 mg/dL | 136 | 136 mmol/L Corrected sodium in range (135–145) | Match |
Sodium Corrected for Hyperglycaemia Nephrology & Electrolytes | Na 128, glucose 33.3 mmol/L | 136 | 136 mmol/L Corrected sodium in range (135–145) | Match |
Calcium Corrected for Albumin Nephrology & Electrolytes | Calcium 7.6 mg/dL, albumin 1.8 g/dL | 9.36 | 9.36 mg/dL Corrected calcium in range (8.5–10.5 mg/dL) | Match |
Calcium Corrected for Albumin Nephrology & Electrolytes | Calcium 1.90 mmol/L, albumin 18 g/L | 9.38 | 9.38 mg/dL Corrected calcium in range (8.5–10.5 mg/dL) | Match |
CURB-65 Pneumonia Severity Emergency & Critical Care | Confusion, raised urea, RR 32 | 3 | Score 3 / 5 High risk (3–5) | Match |
CURB-65 Pneumonia Severity Emergency & Critical Care | Age 70 only | 1 | Score 1 / 5 Low risk (0–1) | Match |
Glasgow Coma Scale Emergency & Critical Care | E3 V4 M5 | 12 | GCS 12 (E3 V4 M5) 9–12 — moderate impairment | Match |
Glasgow Coma Scale Emergency & Critical Care | E1 V1 M4 | 6 | GCS 6 (E1 V1 M4) 3–8 — severe impairment | Match |
Glasgow Coma Scale Emergency & Critical Care | Intubated: E3 VT M5 | 8 | GCS E3 VT M5 Report the components: motor score 5 | Match |
qSOFA Emergency & Critical Care | RR 24 and systolic 95 | 2 | Score 2 / 3 Positive (≥ 2) | Match |
qSOFA Emergency & Critical Care | RR 24 only | 1 | Score 1 / 3 Negative (0–1) | Match |
Mean Arterial Pressure Emergency & Critical Care | 82/50 mmHg | 60.7 | 60.7 mmHg Below 65 mmHg | Match |
Mean Arterial Pressure Emergency & Critical Care | 120/80 mmHg | 93.3 | 93.3 mmHg 65 mmHg or above | Match |
Parkland Formula Emergency & Critical Care | 80 kg, 40% TBSA | 12800 | 12,800 mL in 24 h 800 mL/h for the first 8 h, then 400 mL/h | Match |
Parkland Formula Emergency & Critical Care | 20 kg child, 15% TBSA | 1200 | 1,200 mL in 24 h 75 mL/h for the first 8 h, then 38 mL/h | Match |
Parkland Formula Emergency & Critical Care | 80 kg, 40% TBSA, 2 h after the burn, 1 L given | 12800 | 12,800 mL in 24 h Run 900 mL/h now until hour 8, then 400 mL/h | Match |
Parkland Formula Emergency & Critical Care | 80 kg, 40% TBSA, 10 h after the burn, 6 L given | 12800 | 12,800 mL in 24 h Run 486 mL/h now until hour 24 | Match |
MELD-Na (2016) Gastroenterology & Hepatology | Cr 1.9, bilirubin 4.2, INR 1.2, Na 129 | 25 | MELD-Na 25 Estimated 3-month mortality about 20% | Match |
MELD-Na (2016) Gastroenterology & Hepatology | All values normal | 6 | MELD-Na 6 Estimated 3-month mortality about 2% | Match |
MELD-Na (2016) Gastroenterology & Hepatology | On dialysis, bilirubin 10, INR 2.5, Na 130 | 39 | MELD-Na 39 Estimated 3-month mortality about 53% | Match |
Child-Pugh Score Gastroenterology & Hepatology | Bilirubin 2.5, albumin 3.0, INR 1.8, slight ascites, no encephalopathy | 9 | Class B (9 points) Child-Pugh class B | Match |
Child-Pugh Score Gastroenterology & Hepatology | All normal | 5 | Class A (5 points) Child-Pugh class A | Match |
Glasgow-Blatchford Bleeding Score Gastroenterology & Hepatology | BUN 30, Hb 9 (male), systolic 95, pulse 110, melaena | 14 | Score 14 / 23 Score ≥ 6 — high risk | Match |
Glasgow-Blatchford Bleeding Score Gastroenterology & Hepatology | BUN 12, Hb 14 (male), systolic 125, pulse 80 | 0 | Score 0 / 23 Score 0 — very low risk | Match |
Glasgow-Blatchford Bleeding Score Gastroenterology & Hepatology | Blood urea 40 mg/dL (BUN 18.7), Hb 14 (male), systolic 125, pulse 80 | 2 | Score 2 / 23 Score 2–5 — admit | Match |
Glasgow-Blatchford Bleeding Score Gastroenterology & Hepatology | Urea 9 mmol/L, Hb 110 g/L (female), systolic 105, pulse 90 | 5 | Score 5 / 23 Score 2–5 — admit | Match |
Alvarado Score Gastroenterology & Hepatology | All eight findings | 10 | Score 10 / 10 7–10 — probable appendicitis | Match |
Alvarado Score Gastroenterology & Hepatology | RLQ tenderness and leukocytosis only | 4 | Score 4 / 10 0–4 — appendicitis unlikely | Match |
Modified Centor (McIsaac) Score General & Paediatrics | 10-year-old with all four findings | 5 | Score 5 ≥ 4 — test; high probability | Match |
Modified Centor (McIsaac) Score General & Paediatrics | 50-year-old with fever and cough | 0 | Score 0 ≤ 0 — streptococcal infection unlikely | Match |
Maintenance Fluids (Holliday-Segar 4-2-1) General & Paediatrics | 8 kg infant | 32 | 32 mL/h 768 mL per 24 h | Match |
Maintenance Fluids (Holliday-Segar 4-2-1) General & Paediatrics | 15 kg child | 50 | 50 mL/h 1,200 mL per 24 h | Match |
Maintenance Fluids (Holliday-Segar 4-2-1) General & Paediatrics | 25 kg child | 65 | 65 mL/h 1,560 mL per 24 h | Match |
Apgar Score General & Paediatrics | Vigorous term newborn | 10 | Apgar 10 / 10 7–10 — reassuring | Match |
Apgar Score General & Paediatrics | Acrocyanosis, HR 90, grimace, some flexion, weak cry | 5 | Apgar 5 / 10 4–6 — moderately abnormal | Match |
Caprini Risk Assessment Model for VTE General & Paediatrics | No risk factors, aged 35 | 0 | Score 0 Very low risk (Caprini 0) | Match |
Caprini Risk Assessment Model for VTE General & Paediatrics | Aged 45, minor surgery | 2 | Score 2 Low risk (Caprini 2) | Match |
Caprini Risk Assessment Model for VTE General & Paediatrics | Aged 65, laparoscopic surgery over 45 minutes | 4 | Score 4 Moderate risk (Caprini 4) | Match |
Caprini Risk Assessment Model for VTE General & Paediatrics | Aged 78, hip fracture, previous VTE, BMI 31, confined to bed, major open surgery | 16 | Score 16 High risk (Caprini 16) | Match |
Revised Cardiac Risk Index (Lee) Cardiology & Vascular | No predictor | 0 | RCRI 0 (Class I) Class I: no predictor | Match |
Revised Cardiac Risk Index (Lee) Cardiology & Vascular | Heart failure only | 1 | RCRI 1 (Class II) Class II: 1 predictor | Match |
Revised Cardiac Risk Index (Lee) Cardiology & Vascular | Laparotomy in a man with angina and insulin-treated diabetes | 3 | RCRI 3 (Class IV) Class IV: 3 or more predictors | Match |
Simplified Pulmonary Embolism Severity Index (sPESI) Cardiology & Vascular | No item | 0 | sPESI 0 sPESI 0: low risk | Match |
Simplified Pulmonary Embolism Severity Index (sPESI) Cardiology & Vascular | 85-year-old with cancer | 2 | sPESI 2 sPESI 1 or more: not low risk | Match |
PERC Rule for Pulmonary Embolism Cardiology & Vascular | 30-year-old with pleuritic pain, no criterion | 0 | PERC negative PERC negative: no criterion present | Match |
PERC Rule for Pulmonary Embolism Cardiology & Vascular | 55-year-old on the combined pill | 2 | PERC positive (2 of 8) PERC positive: 2 criteria present | Match |
Bedside Schwartz eGFR for Children Nephrology & Electrolytes | 120 cm child, creatinine 0.5 mg/dL | 99 | 99 mL/min/1.73 m² GFR category G1 | Match |
Bedside Schwartz eGFR for Children Nephrology & Electrolytes | 140 cm child, creatinine 88 µmol/L | 58 | 58 mL/min/1.73 m² GFR category G3a | Match |
NEWS2 (National Early Warning Score 2) Emergency & Critical Care | Normal observations | 0 | NEWS2 0 0–4: low clinical risk | Match |
NEWS2 (National Early Warning Score 2) Emergency & Critical Care | Febrile, tachypnoeic and hypotensive on oxygen | 12 | NEWS2 12 7 or more: high clinical risk | Match |
NEWS2 (National Early Warning Score 2) Emergency & Critical Care | New confusion only | 3 | NEWS2 3 3, with 3 in one parameter: low–medium clinical risk | Match |
NEWS2 (National Early Warning Score 2) Emergency & Critical Care | COPD on scale 2, SpO₂ 95% on oxygen | 4 | NEWS2 4 0–4: low clinical risk | Match |
ABCD² Score for TIA Emergency & Critical Care | Brief sensory symptoms in a 45-year-old | 0 | ABCD² 0 / 7 0–3: low risk | Match |
ABCD² Score for TIA Emergency & Critical Care | 68-year-old, BP 160/95, 30 minutes of arm weakness | 5 | ABCD² 5 / 7 4–5: moderate risk | Match |
ABCD² Score for TIA Emergency & Critical Care | 72-year-old with diabetes, BP 150/90, 2 hours of weakness | 7 | ABCD² 7 / 7 6–7: high risk | Match |
SOFA Score (Sequential Organ Failure Assessment) Emergency & Critical Care | No organ dysfunction | 0 | SOFA 0 / 24 SOFA 0 | Match |
SOFA Score (Sequential Organ Failure Assessment) Emergency & Critical Care | Septic shock on noradrenaline 0.08 µg/kg/min | 12 | SOFA 12 / 24 SOFA 12 | Match |
SOFA Score (Sequential Organ Failure Assessment) Emergency & Critical Care | Ventilated, PaO₂/FiO₂ 90, oliguric | 11 | SOFA 11 / 24 SOFA 11 | Match |
SOFA Score (Sequential Organ Failure Assessment) Emergency & Critical Care | PaO₂/FiO₂ 20 kPa on ventilation, otherwise normal | 3 | SOFA 3 / 24 SOFA 3 | Match |
FIB-4 Index for Liver Fibrosis Gastroenterology & Hepatology | 50-year-old, AST 30, ALT 40, platelets 250 | 0.95 | FIB-4 0.95 Below 1.30: advanced fibrosis unlikely | Match |
FIB-4 Index for Liver Fibrosis Gastroenterology & Hepatology | 55-year-old, AST 48, ALT 50, platelets 1.8 lakh/µL | 2.07 | FIB-4 2.07 1.30–2.66: indeterminate | Match |
FIB-4 Index for Liver Fibrosis Gastroenterology & Hepatology | 62-year-old, AST 60, ALT 45, platelets 120 | 4.62 | FIB-4 4.62 2.67 or more: advanced fibrosis likely | Match |
Maddrey Discriminant Function for Alcoholic Hepatitis Gastroenterology & Hepatology | PT 25 s (control 12 s), bilirubin 15 mg/dL | 74.8 | Discriminant function 74.8 32 or more: severe alcoholic hepatitis | Match |
Maddrey Discriminant Function for Alcoholic Hepatitis Gastroenterology & Hepatology | PT 14 s (control 12 s), bilirubin 3 mg/dL | 12.2 | Discriminant function 12.2 Below 32: not severe by this function | Match |
Maddrey Discriminant Function for Alcoholic Hepatitis Gastroenterology & Hepatology | PT 18 s (control 12 s), bilirubin 342 µmol/L | 47.6 | Discriminant function 47.6 32 or more: severe alcoholic hepatitis | Match |
BISAP Score for Acute Pancreatitis Gastroenterology & Hepatology | Young patient, no criterion | 0 | BISAP 0 / 5 Below 3: lower risk | Match |
BISAP Score for Acute Pancreatitis Gastroenterology & Hepatology | 65-year-old with SIRS and a pleural effusion | 3 | BISAP 3 / 5 3 or more: higher risk | Match |
Padua Prediction Score for VTE in Medical Inpatients General & Paediatrics | Pneumonia in a 75-year-old | 2 | Padua 2 Below 4: low risk of VTE | Match |
Padua Prediction Score for VTE in Medical Inpatients General & Paediatrics | Bed-bound patient with heart failure and cancer | 7 | Padua 7 4 or more: high risk of VTE | Match |
4Ts Score for Heparin-Induced Thrombocytopenia General & Paediatrics | Classic HIT on day 7 | 8 | 4Ts 8 / 8 6–8: high probability | Match |
4Ts Score for Heparin-Induced Thrombocytopenia General & Paediatrics | Septic patient, fall on day 2 | 1 | 4Ts 1 / 8 0–3: low probability | Match |
4Ts Score for Heparin-Induced Thrombocytopenia General & Paediatrics | Unclear timing, possible other cause | 4 | 4Ts 4 / 8 4–5: intermediate probability | Match |
BMI, Body Surface Area and Ideal Body Weight General & Paediatrics | 70 kg, 170 cm, man | 24.2 | BMI 24.2 kg/m² BMI 24.2: normal range (18.5–24.9) | Match |
BMI, Body Surface Area and Ideal Body Weight General & Paediatrics | 68 kg, 160 cm | 26.6 | BMI 26.6 kg/m² BMI 26.6: overweight (25–29.9) | Match |
BMI, Body Surface Area and Ideal Body Weight General & Paediatrics | 220 lb, 66 in | 35.5 | BMI 35.5 kg/m² BMI 35.5: obesity (30 or more) | Match |
PHQ-9 Depression Questionnaire General & Paediatrics | No symptoms | 0 | PHQ-9 0 / 27 0: none or minimal depressive symptoms | Match |
PHQ-9 Depression Questionnaire General & Paediatrics | Several days for most items | 9 | PHQ-9 9 / 27 9: mild depressive symptoms | Match |
PHQ-9 Depression Questionnaire General & Paediatrics | Most items nearly every day, with thoughts of self-harm | 21 | PHQ-9 21 / 27 21: severe depressive symptoms | Match |
GAD-7 Anxiety Questionnaire General & Paediatrics | Several days for each item | 7 | GAD-7 7 / 21 7: mild anxiety symptoms | Match |
GAD-7 Anxiety Questionnaire General & Paediatrics | Most items more than half the days | 14 | GAD-7 14 / 21 14: moderate anxiety symptoms | Match |
NIH Stroke Scale (NIHSS) Emergency & Critical Care | Normal examination | 0 | NIHSS 0 / 42 0: no stroke symptoms | Match |
NIH Stroke Scale (NIHSS) Emergency & Critical Care | Mild facial palsy and slurred speech only | 2 | NIHSS 2 / 42 2: minor stroke | Match |
NIH Stroke Scale (NIHSS) Emergency & Critical Care | Right arm and leg drift, mild aphasia and sensory loss | 7 | NIHSS 7 / 42 7: moderate stroke | Match |
NIH Stroke Scale (NIHSS) Emergency & Critical Care | Right hemisphere stroke: left hemiparesis, gaze palsy, hemianopia and neglect | 18 | NIHSS 18 / 42 18: moderate to severe stroke | Match |
NIH Stroke Scale (NIHSS) Emergency & Critical Care | Drowsy, global aphasia, dense right hemiplegia, forced gaze | 25 | NIHSS 25 / 42 25: severe stroke | Match |
NIH Stroke Scale (NIHSS) Emergency & Critical Care | Left above-knee amputation: that leg untestable | 6 | NIHSS 6 / 42 6 (1 untestable): moderate stroke | Match |
APACHE II Score Emergency & Critical Care | 40-year-old with normal values | 0 | APACHE II 0 / 71 APACHE II 0: acute physiology 0, age 0, chronic health 0 | Match |
APACHE II Score Emergency & Critical Care | 68-year-old with severe pneumonia on FiO₂ 0.4 | 28 | APACHE II 28 / 71 APACHE II 28: acute physiology 23, age 5, chronic health 0 | Match |
APACHE II Score Emergency & Critical Care | 55-year-old with cirrhosis after emergency laparotomy, FiO₂ 0.6, acute renal failure, no blood gas pH | 35 | APACHE II 35 / 71 APACHE II 35: acute physiology 27, age 3, chronic health 5 | Match |
APACHE II Score Emergency & Critical Care | 78-year-old after elective surgery, SI units: PaO₂ 8 kPa on 35%, creatinine 150 µmol/L | 13 | APACHE II 13 / 71 APACHE II 13: acute physiology 5, age 6, chronic health 2 | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Adult, 30 kg (25–34 kg band) | 2 | 2 tablets of 4FDC a day, then 2 of 3FDC Weight band 25–34 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Adult, 45 kg (35–49 kg band) | 3 | 3 tablets of 4FDC a day, then 3 of 3FDC Weight band 35–49 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Adult, 60 kg (50–64 kg band) | 4 | 4 tablets of 4FDC a day, then 4 of 3FDC Weight band 50–64 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Adult, 70 kg (65–75 kg band) | 5 | 5 tablets of 4FDC a day, then 5 of 3FDC Weight band 65–75 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Adult, 80 kg (over 75 kg) | 6 | 6 tablets of 4FDC a day, then 6 of 3FDC Weight band over 75 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Child, 6 kg (4–7 kg band) | 1 | 1 dispersible HRZ + 1 ethambutol 100 mg a day Weight band 4–7 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Child, 20 kg (16–24 kg band) | 4 | 4 dispersible HRZ + 4 ethambutol 100 mg a day Weight band 16–24 kg | Match |
TB First-Line Doses by Weight Band (NTEP) Drug Doses | Child, 27 kg (25–29 kg band) | 3 | 3 dispersible HRZ + 1 adult 4FDC + 3 ethambutol 100 mg a day Weight band 25–29 kg | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 3HP, 10 years, 20 kg (16–23 kg band) | 3 | 3 tablets of isoniazid–rifapentine 150/150 mg once a week Ages 2–14, weight band 16–23 kg | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 3HP, 30 years, 60 kg | 3 | 3 tablets of isoniazid–rifapentine 300/300 mg once a week Over 14 years, 30 kg or more | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 6H, 30 years, 60 kg (5 mg/kg) | 300 | 300 mg isoniazid once a day 5 mg/kg/day | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 6H, 5 years, 18 kg (10 mg/kg) | 180 | 180 mg isoniazid once a day 10 mg/kg/day | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 6H, 40 years, 70 kg (capped at 300 mg) | 300 | 300 mg isoniazid once a day 5 mg/kg/day, capped at 300 mg | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 4R, 6 years, 20 kg (15 mg/kg) | 300 | 300 mg rifampicin once a day 15 mg/kg/day | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 4R, 30 years, 70 kg (capped at 600 mg) | 600 | 600 mg rifampicin once a day 10 mg/kg/day, capped at 600 mg | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 6Lfx, 30 years, 40 kg | 750 | Levofloxacin 750 mg once a day Under 45 kg | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 6Lfx, 30 years, 60 kg | 1000 | Levofloxacin 1000 mg once a day 45 kg or more | Match |
TB Preventive Treatment Doses (NTEP) Drug Doses | 6Lfx, 8 years, 20 kg (16–23 kg band) | 300 | Levofloxacin 300–400 mg once a day Weight band 16–23 kg | Match |
Severe Dehydration, Plan C (IMNCI) Drug Doses | Infant, 6 kg | 600 | 600 mL Ringer's lactate 180 mL over 1 hour (180 mL/h), then 420 mL over 5 hours (84 mL/h) | Match |
Severe Dehydration, Plan C (IMNCI) Drug Doses | Child, 12 kg | 1200 | 1200 mL Ringer's lactate 360 mL over 30 minutes (720 mL/h), then 840 mL over 2½ hours (336 mL/h) | Match |
Antibiotics for Severe Acute Malnutrition (F-IMNCI) Drug Doses | 8 kg, uncomplicated: amoxicillin 120 mg | 120 | Amoxicillin 120 mg three times a day Oral amoxicillin 15 mg/kg/dose, three times a day for 5 days | Match |
Antibiotics for Severe Acute Malnutrition (F-IMNCI) Drug Doses | 8 kg, complicated: ampicillin 400 mg | 400 | Ampicillin 400 mg every 6 hours + gentamicin 60 mg once a day Injectable ampicillin 50 mg/kg/dose 6-hourly and gentamicin 7.5 mg/kg once a day, for 7 days | Match |
Antibiotics for Severe Acute Malnutrition (F-IMNCI) Drug Doses | 10 kg, septic shock: ceftriaxone 500 mg twice a day | 500 | Ceftriaxone 500 mg every 12 hours, or cefotaxime 500 mg every 8 hours, with gentamicin Ceftriaxone 100 mg/kg/day in 2 divided doses, or cefotaxime 150 mg/kg/day in 3, with gentamicin once a day, for 10–14 days | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Lorazepam IV, 20 kg | 2 | Lorazepam IV 2 mg 0.1 mg/kg, at most 4 mg a dose | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Lorazepam IV, 50 kg (capped at 4 mg) | 4 | Lorazepam IV 4 mg 0.1 mg/kg, at most 4 mg a dose (capped) | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Diazepam rectal, 12 kg | 6 | Diazepam rectal 6 mg 0.5 mg/kg, at most 20 mg a dose | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Midazolam buccal, 15 kg | 7.5 | Midazolam buccal 7.5 mg 0.5 mg/kg, at most 10 mg a dose | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Phenytoin IV, 25 kg | 500 | Phenytoin IV/IO 500 mg 20 mg/kg, at most 1,000 mg a dose | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Phenytoin IV, 60 kg (capped at 1,000 mg) | 1000 | Phenytoin IV/IO 1000 mg 20 mg/kg, at most 1,000 mg a dose (capped) | Match |
Status Epilepticus Drug Doses in Children Drug Doses | Levetiracetam IV, 20 kg (20–60 mg/kg) | 400 | Levetiracetam IV 400–1200 mg 20–60 mg/kg, at most 2,500 mg a dose | Match |
Convulsions in a Young Infant (IMNCI) Drug Doses | Diazepam IV, 3 kg | 0.75 | Diazepam IV: 0.75 mg (0.15 mL of 10 mg/2 mL) 0.25 mg/kg (0.05 mL/kg of 10 mg/2 mL) | Match |
Convulsions in a Young Infant (IMNCI) Drug Doses | Diazepam rectal, 4 kg | 2 | Diazepam rectally: 2 mg (0.4 mL of 10 mg/2 mL) 0.5 mg/kg (0.1 mL/kg of 10 mg/2 mL) | Match |
Convulsions in a Young Infant (IMNCI) Drug Doses | Phenobarbital IM, 2.5 kg | 50 | Phenobarbital IM: 50 mg (0.25 mL of 200 mg/mL) 20 mg/kg (0.1 mL/kg of 200 mg/mL) | Match |
Dextrose and Fluid Bolus for a Sick Child (F-IMNCI) Drug Doses | 12 kg | 60 | 10% dextrose 60 mL; saline bolus 240 mL 5 mL/kg of 10% dextrose if hypoglycaemic; 20 mL/kg of normal saline if there are signs of shock | Match |
Dextrose and Fluid Bolus for a Sick Child (F-IMNCI) Drug Doses | 8 kg | 40 | 10% dextrose 40 mL; saline bolus 160 mL 5 mL/kg of 10% dextrose if hypoglycaemic; 20 mL/kg of normal saline if there are signs of shock | Match |
Severe Malaria, Parenteral Doses (NVBDCP) Drug Doses | Artesunate, 50 kg | 120 | Artesunate 120 mg IV or IM at 0, 12 and 24 hours, then once a day 2.4 mg/kg on admission, at 12 h and at 24 h, then once a day | Match |
Severe Malaria, Parenteral Doses (NVBDCP) Drug Doses | Artesunate, 15 kg | 36 | Artesunate 36 mg IV or IM at 0, 12 and 24 hours, then once a day 2.4 mg/kg on admission, at 12 h and at 24 h, then once a day | Match |
Severe Malaria, Parenteral Doses (NVBDCP) Drug Doses | Artemether, 50 kg | 160 | Artemether 160 mg IM, then 80 mg a day 3.2 mg/kg IM on admission, then 1.6 mg/kg a day | Match |
Severe Malaria, Parenteral Doses (NVBDCP) Drug Doses | Quinine, 60 kg | 1200 | Quinine 1200 mg loading, then 600 mg three times a day 20 mg/kg loading dose, at no more than 5 mg/kg per hour, then 10 mg/kg three times a day | Match |
Artemether–Lumefantrine (ACT-AL) by Weight Drug Doses | 10 kg | 1 | 1 tablet a dose, 6 doses over 3 days 5 to under 15 kg: 1 at once, 1 again after 8 hours, then 1 twice daily for 2 days (6 tablets in all) | Match |
Artemether–Lumefantrine (ACT-AL) by Weight Drug Doses | 20 kg | 2 | 2 tablets a dose, 6 doses over 3 days 15 to under 25 kg: 2 at once, 2 again after 8 hours, then 2 twice daily for 2 days (12 tablets in all) | Match |
Artemether–Lumefantrine (ACT-AL) by Weight Drug Doses | 30 kg | 3 | 3 tablets a dose, 6 doses over 3 days 25 to under 35 kg: 3 at once, 3 again after 8 hours, then 3 twice daily for 2 days (18 tablets in all) | Match |
Artemether–Lumefantrine (ACT-AL) by Weight Drug Doses | 60 kg | 4 | 4 tablets a dose, 6 doses over 3 days 35 kg or more: 4 at once, 4 again after 8 hours, then 4 twice daily for 2 days (24 tablets in all) | Match |
Primaquine for P. vivax (NCVBDC) Drug Doses | 60 kg | 15 | Primaquine 15 mg a day for 14 days 0.25 mg/kg a day, 210 mg in all | Match |
Primaquine for P. vivax (NCVBDC) Drug Doses | 20 kg | 5 | Primaquine 5 mg a day for 14 days 0.25 mg/kg a day, 70 mg in all | Match |
Rabies Immunoglobulin, Maximum Dose (NCDC) Drug Doses | 60 kg, human RIG 150 IU/mL | 1200 | At most 1200 IU (8 mL) 20 IU/kg, the maximum for human RIG | Match |
Rabies Immunoglobulin, Maximum Dose (NCDC) Drug Doses | 20 kg, equine RIG 300 IU/mL | 800 | At most 800 IU (2.7 mL) 40 IU/kg, the maximum for equine RIG | Match |
Adrenaline for Anaphylaxis by Age (MoHFW) Drug Doses | 3-month-old | 0.05 | 0.05 mL of adrenaline 1:1000 IM 0–1 year: 0.05 mL (2 units on a 40-unit insulin syringe) | Match |
Adrenaline for Anaphylaxis by Age (MoHFW) Drug Doses | 2-year-old | 0.1 | 0.1 mL of adrenaline 1:1000 IM 1–6 years: 0.1 mL (4 units on a 40-unit insulin syringe) | Match |
Adrenaline for Anaphylaxis by Age (MoHFW) Drug Doses | 10-year-old | 0.2 | 0.2 mL of adrenaline 1:1000 IM 6–12 years: 0.2 mL (8 units on a 40-unit insulin syringe) | Match |
Adrenaline for Anaphylaxis by Age (MoHFW) Drug Doses | 15-year-old | 0.3 | 0.3 mL of adrenaline 1:1000 IM 12–18 years: 0.3 mL (12 units on a 40-unit insulin syringe) | Match |
Adrenaline for Anaphylaxis by Age (MoHFW) Drug Doses | Adult | 0.5 | 0.5 mL of adrenaline 1:1000 IM Adult: 0.5 mL (20 units on a 40-unit insulin syringe) | Match |
IV Paracetamol (Acetaminophen) by Age and Weight Drug Doses | Child, 20 kg | 300 | 300 mg IV every 6 hours 15 mg/kg every 6 hours, or 12.5 mg/kg every 4 hours (at least 4 hours apart); at most 1500 mg a day (75 mg/kg) | Match |
IV Paracetamol (Acetaminophen) by Age and Weight Drug Doses | Neonate, 3 kg | 37.5 | 37.5 mg IV every 6 hours (at least 6 hours apart) 12.5 mg/kg every 6 hours (at least 6 hours apart); at most 150 mg a day (50 mg/kg) | Match |
IV Paracetamol (Acetaminophen) by Age and Weight Drug Doses | Infant, 8 kg | 120 | 120 mg IV every 6 hours (at least 6 hours apart) 15 mg/kg every 6 hours (at least 6 hours apart); at most 480 mg a day (60 mg/kg) | Match |
IV Paracetamol (Acetaminophen) by Age and Weight Drug Doses | Adult, 70 kg | 1000 | 1000 mg IV every 6 hours 1000 mg every 6 hours, or 650 mg every 4 hours (at least 4 hours apart); at most 4000 mg a day | Match |
IV Paracetamol (Acetaminophen) by Age and Weight Drug Doses | Adult, 45 kg | 675 | 675 mg IV every 6 hours 15 mg/kg every 6 hours, or 12.5 mg/kg every 4 hours (at least 4 hours apart); at most 3375 mg a day (75 mg/kg) | Match |
Enoxaparin Dose by Indication and Kidney Function Drug Doses | DVT at home, 70 kg | 70 | 70 mg subcutaneously every 12 hours 1 mg/kg every 12 hours | Match |
Enoxaparin Dose by Indication and Kidney Function Drug Doses | DVT with PE in hospital, once daily, 70 kg | 105 | 105 mg subcutaneously once a day 1.5 mg/kg once a day, at the same time each day | Match |
Enoxaparin Dose by Indication and Kidney Function Drug Doses | DVT, 70 kg, creatinine clearance 25 mL/min | 70 | 70 mg subcutaneously once a day 1 mg/kg once a day (creatinine clearance below 30 mL/min) | Match |
Enoxaparin Dose by Indication and Kidney Function Drug Doses | Prophylaxis, medical patient | 40 | 40 mg subcutaneously once a day 40 mg once a day | Match |
Enoxaparin Dose by Indication and Kidney Function Drug Doses | Prophylaxis, creatinine clearance 20 mL/min | 30 | 30 mg subcutaneously once a day 30 mg once a day (creatinine clearance below 30 mL/min) | Match |
Enoxaparin Dose by Indication and Kidney Function Drug Doses | Unstable angina, 80 kg | 80 | 80 mg subcutaneously every 12 hours 1 mg/kg every 12 hours | Match |
Gentamicin Dose by Age and Weight Drug Doses | Adult, serious infection, 70 kg | 70 | 70 mg every 8 hours 1 mg/kg every 8 hours (3 mg/kg a day) | Match |
Gentamicin Dose by Age and Weight Drug Doses | Adult, life-threatening infection, 60 kg | 102 | 102 mg every 8 hours 1.7 mg/kg every 8 hours (5.1 mg/kg a day) | Match |
Gentamicin Dose by Age and Weight Drug Doses | Child, 20 kg | 40 | 40–50 mg every 8 hours 2–2.5 mg/kg every 8 hours (6–7.5 mg/kg a day) | Match |
Gentamicin Dose by Age and Weight Drug Doses | Infant, 5 kg | 12.5 | 12.5 mg every 8 hours 2.5 mg/kg every 8 hours (7.5 mg/kg a day) | Match |
Gentamicin Dose by Age and Weight Drug Doses | Neonate under a week old, 3 kg | 7.5 | 7.5 mg every 12 hours 2.5 mg/kg every 12 hours (5 mg/kg a day) | Match |
Ceftriaxone Dose by Indication Drug Doses | Meningitis, 20 kg child | 2000 | 2000 mg first, then 2000 mg a day 100 mg/kg first (at most 4 g), then 100 mg/kg a day (at most 4 g a day) | Match |
Ceftriaxone Dose by Indication Drug Doses | Meningitis, 50 kg child (capped at 4 g) | 4000 | 4000 mg first, then 4000 mg a day 100 mg/kg first (at most 4 g), then 100 mg/kg a day (at most 4 g a day), capped | Match |
Ceftriaxone Dose by Indication Drug Doses | Serious infection, 20 kg child | 1000 | 1000–1500 mg a day, divided every 12 hours 50 to 75 mg/kg a day, divided every 12 hours; at most 2 g a day | Match |
Ceftriaxone Dose by Indication Drug Doses | Otitis media, 30 kg child (capped at 1 g) | 1000 | 1000 mg IM, once A single intramuscular dose of 50 mg/kg, at most 1 g (capped) | Match |
IV Vancomycin Dose by Age Drug Doses | Adult | 2000 | 2 g a day: 500 mg every 6 hours or 1 g every 12 hours Usual adult daily dose 2 g, with normal renal function | Match |
IV Vancomycin Dose by Age Drug Doses | Child, 20 kg | 200 | 200 mg every 6 hours 10 mg/kg every 6 hours | Match |
IV Vancomycin Dose by Age Drug Doses | Neonate in the first week, 3 kg | 45 | 45 mg first, then 30 mg every 12 hours 15 mg/kg first, then 10 mg/kg every 12 hours | Match |
IV Vancomycin Dose by Age Drug Doses | Neonate after the first week, 4 kg | 60 | 60 mg first, then 40 mg every 8 hours 15 mg/kg first, then 10 mg/kg every 8 hours | Match |
IV Acyclovir Dose by Infection and Age Drug Doses | HSV encephalitis, adult 70 kg | 700 | 700 mg IV every 8 hours for 10 days 10 mg/kg infused over 1 hour every 8 hours, for 10 days | Match |
IV Acyclovir Dose by Infection and Age Drug Doses | HSV encephalitis, child 20 kg | 400 | 400 mg IV every 8 hours for 10 days 20 mg/kg infused over 1 hour every 8 hours, for 10 days | Match |
IV Acyclovir Dose by Infection and Age Drug Doses | Neonatal HSV, 3 kg | 30 | 30 mg IV every 8 hours for 10 days 10 mg/kg infused over 1 hour every 8 hours, for 10 days | Match |
IV Acyclovir Dose by Infection and Age Drug Doses | Zoster, immunocompromised child 15 kg | 300 | 300 mg IV every 8 hours for 7 days 20 mg/kg infused over 1 hour every 8 hours, for 7 days | Match |
Oral Amoxicillin by Infection and Weight Drug Doses | 20 kg, mild ear infection, every 12 hours | 250 | 250 mg every 12 hours 25 mg/kg/day divided every 12 hours (500 mg a day) | Match |
Oral Amoxicillin by Infection and Weight Drug Doses | 20 kg, chest infection, every 8 hours | 266.7 | 266.7 mg every 8 hours 40 mg/kg/day divided every 8 hours (800 mg a day) | Match |
Oral Amoxicillin by Infection and Weight Drug Doses | 50 kg, severe infection, every 12 hours | 875 | 875 mg every 12 hours 40 kg or more: 875 mg every 12 hours | Match |
Oral Amoxicillin by Infection and Weight Drug Doses | 2-month-old, 5 kg | 75 | At most 75 mg every 12 hours The upper dose up to 3 months of age: 30 mg/kg/day divided every 12 hours | Match |
Oral Azithromycin for Children by Infection Drug Doses | Otitis media, single dose, 15 kg | 450 | 450 mg once 30 mg/kg once | Match |
Oral Azithromycin for Children by Infection Drug Doses | Pneumonia, 20 kg | 200 | 200 mg on day 1, then 100 mg daily for 4 days 10 mg/kg on day 1, then 5 mg/kg once daily on days 2 to 5 | Match |
Oral Azithromycin for Children by Infection Drug Doses | Pharyngitis, 25 kg | 300 | 300 mg once daily for 5 days 12 mg/kg once daily for 5 days | Match |
Cefixime Dose for Children and Adults Drug Doses | Child, 15 kg, once daily | 120 | 120 mg once daily 8 mg/kg once daily | Match |
Cefixime Dose for Children and Adults Drug Doses | Child, 15 kg, every 12 hours | 60 | 60 mg every 12 hours 4 mg/kg every 12 hours (8 mg/kg/day) | Match |
Cefixime Dose for Children and Adults Drug Doses | Adult | 400 | 400 mg daily Adults: 400 mg daily | Match |
Metronidazole for Amoebiasis Drug Doses | Child, 20 kg | 233.3 | 233.3–333.3 mg three times daily for 10 days 35 to 50 mg/kg a day in three doses (700–1000 mg a day), for 10 days | Match |
Metronidazole for Amoebiasis Drug Doses | Adult, amoebic dysentery | 750 | 750 mg three times daily for 5 to 10 days Adults, acute intestinal amoebiasis: 750 mg orally three times daily, 5 to 10 days | Match |
Albendazole for Neurocysticercosis or Hydatid Disease Drug Doses | Neurocysticercosis, 40 kg | 300 | 300 mg twice daily with meals 15 mg/kg/day in two doses, at most 800 mg a day; 8 to 30 days | Match |
Albendazole for Neurocysticercosis or Hydatid Disease Drug Doses | Hydatid disease, 70 kg | 400 | 400 mg twice daily with meals 60 kg or more: 400 mg twice daily; 28-day cycles, each followed by 14 days without albendazole, for 3 cycles | Match |
Albendazole for Neurocysticercosis or Hydatid Disease Drug Doses | Neurocysticercosis, 58 kg (capped at 800 mg a day) | 400 | 400 mg twice daily with meals 15 mg/kg/day in two doses, at most 800 mg a day (capped); 8 to 30 days | Match |
Oseltamivir for Influenza by Age and Weight Drug Doses | Treatment, child 1–12 years, 12 kg | 30 | 30 mg twice daily for 5 days 30 mg (5 mL of the 6 mg/mL suspension) twice daily for 5 days | Match |
Oseltamivir for Influenza by Age and Weight Drug Doses | Treatment, child, 20 kg | 45 | 45 mg twice daily for 5 days 45 mg (7.5 mL of the 6 mg/mL suspension) twice daily for 5 days | Match |
Oseltamivir for Influenza by Age and Weight Drug Doses | Prophylaxis, child, 30 kg | 60 | 60 mg once daily for 10 days 60 mg (10 mL of the 6 mg/mL suspension) once daily for 10 days | Match |
Oseltamivir for Influenza by Age and Weight Drug Doses | Treatment, infant, 6 kg | 18 | 18 mg twice daily for 5 days 3 mg/kg twice daily (3 mL of the 6 mg/mL suspension) | Match |
Oseltamivir for Influenza by Age and Weight Drug Doses | Treatment, adult | 75 | 75 mg twice daily for 5 days 75 mg twice daily for 5 days | Match |
Oral Doxycycline for Children and Adults Drug Doses | Severe infection, 20 kg child | 44 | 44 mg every 12 hours Under 45 kg, severe or life-threatening infection: 2.2 mg/kg every 12 hours | Match |
Oral Doxycycline for Children and Adults Drug Doses | Less severe, 30 kg child | 66 | 66 mg twice on day 1, then 66 mg a day Older than 8 years and under 45 kg: 4.4 mg/kg in two doses on day 1, then 2.2 mg/kg a day (once, or in two doses) | Match |
Oral Doxycycline for Children and Adults Drug Doses | Severe infection, 60 kg | 100 | 100 mg every 12 hours 45 kg or more: the adult dose | Match |
Co-trimoxazole (Sulfamethoxazole–Trimethoprim) by Weight Drug Doses | Urinary tract infection, 20 kg child | 80 | 80 mg trimethoprim (400 mg sulfamethoxazole) every 12 hours for 10 days 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole a day, in two doses, for 10 days | Match |
Co-trimoxazole (Sulfamethoxazole–Trimethoprim) by Weight Drug Doses | Shigellosis, 15 kg child | 60 | 60 mg trimethoprim (300 mg sulfamethoxazole) every 12 hours for 5 days 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole a day, in two doses, for 5 days | Match |
Co-trimoxazole (Sulfamethoxazole–Trimethoprim) by Weight Drug Doses | Pneumocystis pneumonia, 60 kg | 225 | 225–300 mg trimethoprim every 6 hours 15 to 20 mg/kg trimethoprim (75 to 100 mg/kg sulfamethoxazole) a day, every 6 hours, for 14 to 21 days | Match |
IV Ondansetron by Weight Drug Doses | Chemotherapy, 20 kg child | 3 | 3 mg IV, for 3 doses 0.15 mg/kg a dose for 3 doses, at most 16 mg a dose | Match |
IV Ondansetron by Weight Drug Doses | Chemotherapy, 120 kg (capped at 16 mg) | 16 | 16 mg IV, for 3 doses 0.15 mg/kg a dose for 3 doses, at most 16 mg a dose (capped) | Match |
IV Ondansetron by Weight Drug Doses | After surgery, 15 kg child | 1.5 | 1.5 mg IV once 40 kg or less: 0.1 mg/kg | Match |
IV Ondansetron by Weight Drug Doses | After surgery, 45 kg child | 4 | 4 mg IV once More than 40 kg: 4 mg | Match |
Infusion Rate from a Weight-Based Dose Drug Doses | Noradrenaline 4 mg in 50 mL, 70 kg, 0.1 µg/kg/min | 5.25 | 5.25 mL/h 0.1 µg/kg/min at 80 µg/mL | Match |
Infusion Rate from a Weight-Based Dose Drug Doses | Dobutamine 250 mg in 50 mL, 60 kg, 5 µg/kg/min | 3.6 | 3.6 mL/h 5 µg/kg/min at 5000 µg/mL | Match |
IV Drip Rate in Drops per Minute Drug Doses | 1,000 mL over 8 hours, 20 drops/mL | 42 | 42 drops/min 125 mL/h with a 20 drops/mL set | Match |
IV Drip Rate in Drops per Minute Drug Doses | 500 mL over 4 hours, 60 drops/mL | 125 | 125 drops/min 125 mL/h with a 60 drops/mL set | Match |
Morphine Milligram Equivalents per Day (CDC 2022) Drug Doses | Hydrocodone 5 mg four times a day (CDC's example) | 20 | 20 MME/day 20 MME/day: below 50 | Match |
Morphine Milligram Equivalents per Day (CDC 2022) Drug Doses | Extended-release oxycodone 10 mg twice a day (CDC's example) | 30 | 30 MME/day 30 MME/day: below 50 | Match |
Morphine Milligram Equivalents per Day (CDC 2022) Drug Doses | Tramadol 100 mg three times a day with a 25 µg/h fentanyl patch | 120 | 120 MME/day 120 MME/day: at or above 50 | Match |
The publication behind each formula is listed in How Ayulex is checked. Matching worked examples shows the arithmetic is implemented correctly; it does not validate a score for a particular patient.
Published run: 28 October 2026
Ayulex's production pipeline on each question, graded by rule. An answer that could not be read as a choice counts as wrong.
| Set | Result | 95% CI | Raw outputs |
|---|---|---|---|
| MedQA, random 100 of 1,273 (seed 2026-10) | 94 of 100 | 87.5–97.2% | medqa.jsonl |
| Official sources: CDSCO, NLEM, FDA notices | 62 of 62 | 94.2–100% | official-sources.jsonl |
| Label and calculation cases | 11 of 12 | 64.6–98.5% | label-and-calculation.jsonl |
What these figures do not show
- They are from one run, with the models in use on that date. Ayulex's models have changed since, and a new run is needed to speak for the current setup.
- The samples are small, so the intervals are wide: the 12 label and calculation cases in particular say little on their own.
- 5 of the 6 MedQA questions counted as wrong had no answer at all, because the account's model credit ran out during the run. They count against the score, as the method required on that date. The harness has since changed: such a reply is now recorded as a failed request, and a run with one is marked incomplete until those questions are asked again.
- The official-source questions were built by Ayulex from documents Ayulex also holds, so a high score is expected. They show those lists are used correctly, not general medical knowledge.
- The cases have not yet had clinical review. NEET-PG, MedMCQA and PubMedQA have not been run.
- No comparison with another product is published. The comparison models' runs on that date were cut short by the same credit limit, so comparing them would not be fair. A run of Expert reasoning was cut short too, and is left out for the same reason.
Model accuracy: method
On this page, an accuracy figure is published only from a completed run of this method. No comparison with any other product has been published yet.
- 1Public question sets
MedQA (USMLE-style, four options, test split); the MedMCQA validation split, drawn from AIIMS and NEET-PG papers; and PubMedQA. Questions are not selected by hand: a run uses the whole set or a random sample with a stated seed.
- 2Clinical cases with a marking scheme, 12 cases
Free-text questions on label dosing, contraindications, interactions and calculations, each graded by code against the label sentence it comes from. Every PubMed identifier and DOI an answer cites is looked up to see whether it exists.
- 3Official sources, 62 questions
Yes-or-no questions on CDSCO prohibitions, the National List of Essential Medicines 2022 and FDA safety communications of 2025 and 2026, built from the documents themselves. Each kind has controls whose answer is no, so a system cannot score by always saying yes. Ayulex holds these documents and general models do not; results will be reported as exactly that, not as general medical accuracy.
- 4The same harness for every system
Each system receives the identical question text through one script. Ayulex is called through its own production pipeline; comparison models are called directly. The run date and the cost of each answer are recorded.
- 5Rule-based scoring, published in full
Answers are graded by rule, unparseable answers count as wrong, and accuracy is reported with a 95% confidence interval. Results are published here with the per-question outputs, so anyone can re-score them.